Morning Overview on MSN
Researchers map real-time signals that trigger T cell activation
A cluster of recent studies has sharpened the scientific picture of how T cells switch on, tracking the molecular signals ...
CoRegen, Inc., a biopharmaceutical company pursuing novel treatments for patients impacted by some of the most aggressive forms of canc ...
CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...
Morning Overview on MSN
Prodrug lipid nanoparticle delivers IDO inhibitor and mRNA to fight tumors
Engineers at the University of Pennsylvania have built a lipid nanoparticle that chemically fuses an IDO-pathway inhibitor with the very lipids that carry IL-12 mRNA into tumors, creating a single ...
A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager." This type of immunotherapy ignites our own ...
For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell ...
The current path to CAR-T cell therapy is, by any measure, a logistical ordeal. A patient’s immune cells must be drawn out of ...
A recent Science study explored how intranuclear metabolic enzymes establish the link between locus-specific epigenetic reprogramming of T cells and nutrient availability. Persistent antigen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results